Long-term alpha interferon treatment is effective on anaemia and significantly reduces iron overload in congenital dyserythropoiesis type I
- PMID: 15458519
- DOI: 10.1111/j.1600-0609.2004.00310.x
Long-term alpha interferon treatment is effective on anaemia and significantly reduces iron overload in congenital dyserythropoiesis type I
Abstract
Interferon has been shown to be an effective treatment of congenital dyserythropoiesis type I (CDA-I), but the optimal dose and the feasibility of this treatment remains to be determined. Here, in a 9-yr follow-up of a single patient, we show that interferon remains active during such a long period. The optimal dose of conventional alpha interferon could be evaluated at 2 million units twice a week. Pegylated interferon could be used as well at a dose of 30 microg/wk. During interferon treatment, serum and erythrocyte ferritin levels decreased progressively, and remained inversely correlated with haemoglobin levels. On repeated liver biopsies, iron overload could be normalized. Low dose interferon is a long-term treatment of CDA-I, and allows a significant decrease in iron overload, that could be interesting even in patients who are only moderately anaemic.
Similar articles
-
The pathogenesis, diagnosis and management of congenital dyserythropoietic anaemia type I.Br J Haematol. 2019 May;185(3):436-449. doi: 10.1111/bjh.15817. Epub 2019 Mar 5. Br J Haematol. 2019. PMID: 30836435 Free PMC article. Review.
-
Congenital dyserythropoietic anemia type I with bone abnormalities, mutations of the CDAN I gene, and significant responsiveness to alpha-interferon therapy.Ann Hematol. 2006 Sep;85(9):591-5. doi: 10.1007/s00277-006-0143-z. Epub 2006 Jun 10. Ann Hematol. 2006. PMID: 16767397
-
Successful management of congenital dyserythropoietic anemia type I with interferon alpha in a child.Pediatr Hematol Oncol. 2005 Jun;22(4):265-70. doi: 10.1080/08880010590935149. Pediatr Hematol Oncol. 2005. PMID: 16020112
-
Interferon therapy in congenital dyserythropoietic anemia type I/II.Pediatr Hematol Oncol. 2005 Mar;22(2):133-8. doi: 10.1080/08880010590907221. Pediatr Hematol Oncol. 2005. PMID: 15804998
-
[Successful treatment of congenital dyserythropoietic anemia type I with long-term administration of deferoxamine].Rinsho Ketsueki. 1988 Sep;29(9):1454-9. Rinsho Ketsueki. 1988. PMID: 3063858 Review. Japanese. No abstract available.
Cited by
-
Close to unraveling the secrets of congenital dyserythropoietic anemia types I and II.Haematologica. 2009 May;94(5):599-602. doi: 10.3324/haematol.2009.005785. Haematologica. 2009. PMID: 19407313 Free PMC article.
-
Stem cell transplantation for congenital dyserythropoietic anemia: an analysis from the European Society for Blood and Marrow Transplantation.Haematologica. 2019 Aug;104(8):e335-e339. doi: 10.3324/haematol.2018.206623. Epub 2019 Jan 24. Haematologica. 2019. PMID: 30679331 Free PMC article. No abstract available.
-
The pathogenesis, diagnosis and management of congenital dyserythropoietic anaemia type I.Br J Haematol. 2019 May;185(3):436-449. doi: 10.1111/bjh.15817. Epub 2019 Mar 5. Br J Haematol. 2019. PMID: 30836435 Free PMC article. Review.
-
Congenital dyserythropoietic anemia.Int J Hematol. 2010 Oct;92(3):432-8. doi: 10.1007/s12185-010-0667-9. Epub 2010 Sep 7. Int J Hematol. 2010. PMID: 20820969
-
Congenital Dyserythropoietic Anemia Type 1: Report of One Patient and Analysis of Previously Reported Patients Treated with Interferon Alpha.Indian J Hematol Blood Transfus. 2016 Jun;32(Suppl 1):272-7. doi: 10.1007/s12288-015-0600-8. Epub 2015 Sep 21. Indian J Hematol Blood Transfus. 2016. PMID: 27408411 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources